PUR Biologics, a subsidiary of ORHub, plans to launch its new bone growth product focused on spine surgery in early 4Q22.
“PUR’s Pillars™ design aims to achieve optimal patient outcomes by keeping bone graft materials in place, avoiding the typical migration of bone graft material from the desired location and eliminating inactive carriers,” shared Ryan Fernan, Head of PUR Biologics. “PUR’s Pillars are created from our Fibrous Collagen and deliver a solid matrix structure designed to act as a Bio-active Bridge for a patient’s natural cells and growth factors to bind with.”
Market estimates for “bone growth” products and related therapeutics are believed to be greater than $8B, increasing the opportunity for revenue, value and scalability which ORHub has positioned with the PUR Biologics brand.
PUR Biologics, a subsidiary of ORHub, plans to launch its new bone growth product focused on spine surgery in early 4Q22.
"PUR's Pillars™ design aims to achieve optimal patient outcomes by keeping bone graft materials in place, avoiding the typical migration of bone graft material from the desired location and eliminating inactive carriers,"...
PUR Biologics, a subsidiary of ORHub, plans to launch its new bone growth product focused on spine surgery in early 4Q22.
“PUR’s Pillars™ design aims to achieve optimal patient outcomes by keeping bone graft materials in place, avoiding the typical migration of bone graft material from the desired location and eliminating inactive carriers,” shared Ryan Fernan, Head of PUR Biologics. “PUR’s Pillars are created from our Fibrous Collagen and deliver a solid matrix structure designed to act as a Bio-active Bridge for a patient’s natural cells and growth factors to bind with.”
Market estimates for “bone growth” products and related therapeutics are believed to be greater than $8B, increasing the opportunity for revenue, value and scalability which ORHub has positioned with the PUR Biologics brand.
Copy to clipboard 
